Shares of Valneva SE Sponsored ADR (VALN) have gained 3.5% over the past four weeks to close the last trading session at $7.32, but there could still be a solid upside left in the stock if short-term price targets of Wall Street analysts are any indication. Going by the price targets, the mean estimate of $18.33 indicates a potential upside of 150.4%. The average comprises four short-term price targets ranging from a low of $8.30 to a high of $26, with a standard deviation of $7.63. While the lowest estimat ...

文章核心观点 - 分析师给予Valneva SE Sponsored ADR (VALN)股票的平均目标价为18.33美元,较当前价格上涨135.3%,存在较大上涨潜力 [1][2] - 分析师对公司未来盈利前景持乐观态度,纷纷上调盈利预测,这可能是推动股价上涨的合理原因 [10][11] - 分析师给出的目标价格并不一定能准确预测股价走势,投资者不应完全依赖 [3][5][9] 公司相关 - 公司当前股价为7.79美元,过去4周涨幅为0.7% [1] - 分析师给出的目标价格区间为8.30美元至26美元,标准差为7.63美元 [2] - 公司目前被评为Zacks Rank 2(买入),处于行业前20%,这进一步支持了其短期上涨潜力 [12] 行业相关 - 分析师给出的目标价格往往存在偏高倾向,这可能源于其所在券商的商业利益考虑 [6][7] - 但当分析师对某股票的目标价格预测高度一致时,可能意味着对公司基本面的普遍认同,值得进一步研究 [8]

First-Half Sales Performance in Line with Full-Year 2024 Guidance Total revenues of €70.8 million, including product sales of €68.3 million, in line with anticipated supply and sales phasing Net Profit of €34.0 million, including proceeds from PRV sale Operating profit of €46.7 million compared to an operating loss of €35.0 million in the first half of 2023 Cash position of €131.4 million Substantially lower cash burn expected in the second half of 2024 as Valneva completed its cost contributions to the agr ...

Valneva obtains exclusive worldwide license for LimmaTech's S4V Shigella vaccine candidate and adds an attractive Phase 2 clinical asset to Valneva's R&D pipeline LimmaTech to receive upfront payment, is eligible for future milestone and royalty payments, and will collaborate on S4V clinical development through Phase 2 Valneva will host a live webcast on this announcement at 3 p.m. CEST/9 a.m. EDT today. Please refer to this link: https://edge.media-server.com/mmc/p/ck932u2n Saint-Herblain (France) and Schl ...

Valneva obtains exclusive worldwide license for LimmaTech's S4V Shigella vaccine candidate and adds an attractive Phase 2 clinical asset to Valneva's R&D pipeline LimmaTech to receive upfront payment, is eligible for future milestone and royalty payments, and will collaborate on S4V clinical development through Phase 2 Valneva will host a live webcast on this announcement at 3 p.m. CEST/9 a.m. EDT today. Please refer to this link: https://edge.media-server.com/mmc/p/ck932u2n Saint-Herblain (France) and Schl ...

Valneva to receive up to $41.3 million from CEPI and the European Union to expand access to chikungunya vaccine, IXCHIQ®Funding will support clinical trials in vulnerable groups, such as children and pregnant women Partnership will also support technology transfer to an additional manufacturer to supply IXCHIQ® to Asian LMICsIXCHIQ® is already approved for use in adults 18 years of age and older in the U.S., Canada and Europe Oslo, Norway, and Saint-Herblain, France, July 22, 2024—The Coalition for Epidemi ...

Valneva SE (VALN) recently announced that the European Commission (EC) has given it the marketing authorization for Valneva’s single-dose Chikungunya vaccine, IXCHIQ, in Europe. This approval followed the FDA's nod for IXCHIQ in November 2023.The approval was unanimously endorsed by Member States, followed by a rigorous assessment by the European Medicines Agency.It positions Valneva to protect the lives of European populations against Chikungunya outbreaks and make a significant impact on the Chikungunya v ...

Saint Herblain (France), July 1, 2024 – Valneva SE (NASDAQ:VALN, PARIS:VLA), a specialty vaccine company, today announced that the European Commission (EC) has granted marketing authorization in Europe for Valneva's single-dose vaccine, IXCHIQ®, for the prevention of disease caused by the chikungunya virus in individuals 18 years of age and older. The approval was unanimously endorsed by Member States following a stringent assessment by the European Medicines Agency (EMA)1. The EC decision marks the third a ...

Saint Herblain (France), July 1, 2024 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, today announced that the European Commission (EC) has granted marketing authorization in Europe for Valneva’s single-dose vaccine, IXCHIQ®, for the prevention of disease caused by the chikungunya virus in individuals 18 years of age and older. The approval was unanimously endorsed by Member States following a stringent assessment by the European Medicines Agency (EMA)1. The EC decision marks ...

Saint-Herblain (France), June 26, 2024 – Valneva SE (NASDAQ:VALN, PARIS:VLA), a specialty vaccine company, today announced that all the resolutions recommended by the Board of Directors were approved by the shareholders at its Combined General Meeting (CGM) held today in Lyon, France. Among the adopted resolutions were approval of the 2023 financial statements, delegations for the management board to increase Valneva's share capital and/or issue financial instruments, and the appointment of a new director t ...